ClinicalTrials.gg
CompletedNCT05259722DELTA FORCEUpdated May 9, 2025Results posted

A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema

A Phase 3 interventional study of Delgocitinib and Toctino in Chronic Hand Eczema, sponsored by LEO Pharma. Completed at 102 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-09.

Sponsored by LEO Pharma · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
513
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Eczema by LEO Pharma — 1 open to participants now, 1 under way, none of them phase 3. Eczema · LEO Pharma.

Enrollment
2nd of 12
513 · median 178
Started
2022
with 2 others
Phase 3
7 of 13
none open now
Registered
9th of 13
by date

Among the 13 studies in Eczema by LEO Pharma, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2022, is one of 7 in phase 3, and was the 9th registered.

Eczema

506 studies on the registry are indexed under Eczema; 90 are open to participants now.

Browse Eczema studies →

Open to participants now

1 of the 13 studies in Eczema by LEO Pharma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 66 Eczema studies recruiting now, 31 (47%) set no upper age limit and 27 (41%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Eczema by LEO Pharma, or all of them as a file.
02

Study summary

This is a 24-week study in adult participants with severe chronic hand eczema (CHE) and with a documented inadequate response to treatment with topical corticosteroids (TCS) or for whom TCS are documented to be otherwise medically inadvisable. Eligible participants will be randomised to receive topical administration of delgocitinib cream 20 mg/g, twice-daily, or oral administration of alitretinoin capsules 30 mg (with an option to reduce to 10 mg during trial conduct), once-daily. The participants will visit the clinic regularly to have the study doctor assess their CHE and to answer questions about itch, pain, CHE symptoms, and quality of life.

The purpose of this trial is to compare the efficacy, health-related quality of life, and safety of delgocitinib cream and alitretinoin capsules.

03

Conditions studied

  • Chronic Hand Eczema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main inclusion criteria:

  • Diagnosis of CHE, defined as hand eczema that has persisted for more than 3 months or returned twice or more within the last 12 months.
  • Disease severity graded as severe at screening and baseline according to IGA-CHE (i.e. an IGA-CHE score of 4).
  • Participants who have a documented recent history of inadequate response to treatment with topical (TCS) or for whom TCS are documented to be otherwise medically inadvisable (e.g. due to important side effects or safety risks).
  • Participants adherent to standard non-medicated skin care including avoidance of known and relevant irritants and allergens.
  • Participants must use methods in accordance with local regulations regarding the methods of contraception for those participating in clinical studies

Main exclusion criteria:

  • Concurrent skin diseases on the hands, e.g. tinea manuum.
  • Active atopic dermatitis requiring medical treatment in regions other than the hands and feet.
  • Active psoriasis on any part of the body.
  • Hyperkeratotic hand eczema in combination with a history of psoriasis on any part of the body.
  • infection on the hands.
  • Participants who cannot receive alitretinoin.
  • Clinically significant infection within 28 days prior to baseline which, in the opinion of the investigator, may compromise the safety of the participant in the trial, interfere with evaluation of the IMP, or reduce the participant's ability to participate in the trial.
  • History of any known primary immunodeficiency disorder including a positive (HIV) test at screening, or the participant taking antiretroviral medications as determined by medical history and/or participant's verbal report.
  • Any disorder which is not stable and could:

    • Affect the safety of the participant throughout the trial.
    • Impede the participant's ability to complete the trial.
  • Positive surface antigen or virus antibody serology at screening.
  • Systemic treatment with drugs, immunomodulating drugs, retinoids, or corticosteroids within 28 days prior to baseline.
  • Use of tanning beds, phototherapy, or bleach baths on the hands within 28 days prior to baseline.
  • Previous or current treatment with Janus kinase (JAK) inhibitors (including delgocitinib/LEO 124249), systemic or topical.
  • Cutaneously applied treatment with immunomodulators or TCS on the hands within 14 days prior to baseline.
  • Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 14 days prior to baseline.
  • Other transdermal or cutaneously applied therapy on the hands (except for the use of subject's own emollients) within 7 days prior to baseline.
  • Cutaneously applied treatments in regions other than the hands, which could interfere with clinical trial evaluations or pose a safety concern within 7 days prior to baseline.
  • Treatment with any marketed biological therapy or biologic agents:

    • Any cell-depleting agents: within 6 months prior to baseline, or until lymphocyte count returns to normal, whichever is longer.
    • Other biologics: within 3 months or 5 half-lives, whichever is longer, prior to baseline.
  • Previously used alitretinoin or participated in a clinical trial with alitretinoin or delgocitinib.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
513 participants (actual)

Study arms

  • Experimental
    Delgocitinib cream 20 mg/g

    Twice-daily topical application for up to 24 weeks

    Drug: Delgocitinib

  • Active comparator
    Alitretinoin capsules 30 mg per capsule

    1 capsule per day for up to 24 weeks

    Drug: Toctino

Interventions

  • Cream for topical application 20 mg/g

  • 1 capsule toctino 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur

06

What researchers measure

Primary outcomes

  1. Change in HECSI Score From Baseline to Week 12

    The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score) with a higher score indicating greater severity.

    Time frame: 12 weeks

Secondary outcomes

  1. HECSI-90 at Week 12

    The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score), with a higher score indicating greater severity. HECSI-90 is defined as at least 90% improvement in HECSI score from baseline.

    Time frame: 12 weeks

  2. IGA-CHE TS at Week 12.

    The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's global chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). IGA-CHE treatment success (IGA-CHE TS) is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a ≥2-step improvement from baseline.

    Time frame: 12 weeks

  3. Change in HESD Itch Score (Weekly Average) From Baseline to Week 12

    The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'itch' component.

    Time frame: 12 weeks

  4. Change in HESD Pain Score (Weekly Average) From Baseline to Week 12.

    The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'pain' component.

    Time frame: 12 weeks

  5. AUC of HECSI-90 From Baseline up to Week 24

    The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score) with a higher score indicating greater severity. HECSI-90 is defined as at least 90% improvement in HECSI score from baseline. The area under the curve (AUC) at participant level will be determined as follows: 1 will be assigned when response is observed and 0 otherwise. The AUC is interpreted as number of days with 90% reduction in HECSI score until Week 24.

    Time frame: 24 weeks

  6. AUC of Change From Baseline in DLQI Score up to Week 24

    The Dermatology Life Quality Index (DLQI) is a validated questionnaire consisting of 10 items addressing the participant's perception of the impact of their skin disease on different aspects of their quality of life over the last week. The DLQI score is the sum of the 10 items (score ranging from 0 to 30); a high score is indicative of a poor quality of life. The area under the curve (AUC) at patient level will be determined from the change from baseline in DLQI score estimated as a piecewise linear function from Week 0 to Week 24. Differences will be analyzed with opposite sign to interpret positive area as improvement in scores and negative area as worsening.

    Time frame: 24 weeks

  7. Change in HECSI Score From Baseline to Week 24

    The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score) with a higher score indicating greater severity.

    Time frame: 24 weeks

  8. Number of Treatment-emergent AEs From Baseline up to Week 26

    An adverse event (AE) will be considered treatment emergent if started after the first application of investigational medicinal product (IMP), or if started before the first application of IMP and worsened in severity after first dose of IMP.

    Time frame: 26 weeks

  9. Number of Treatment-emergent SAEs From Baseline up to Week 26

    A serious adverse event (SAE) will be considered treatment emergent if started after the first application of investigational medicinal product (IMP), or if started before the first application of IMP and worsened in severity after first dose of IMP.

    Time frame: 26 weeks

  10. Number of AEs Leading to IMP Discontinuation up to Week 24

    The investigational medicinal product (IMP) will be discontinued permanently in case of an AE that, in the opinion of the investigator or sponsor's medical expert, contraindicates further dosing. The investigator will assess the relationship between investigational medicinal product (IMP) and the adverse event (AE).

    Time frame: 24 weeks

07

Results

Posted Mar 14, 2025

Participant flow

The trial enrolled adult participants with severe CHE and with a documented inadequate response to treatment with TCS or for whom TCS were documented to be otherwise medically inadvisable.

Participant flow — Overall Study
MilestoneDelgocitinib Cream 20 mg/gAlitretinoin Capsules 30 mg Per Capsule
Started254259
Completed219154
Not completed35105
Withdrew: Adverse event224
Withdrew: Lost to follow-up51
Withdrew: Lack of efficacy826
Withdrew: Withdrawal by subject1533
Withdrew: Various reasons39
Withdrew: Not exposed to imp112
Withdrew: Discontinuation of imp, related to covid-1910

Outcome measures

PrimaryChange in HECSI Score From Baseline to Week 12

The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score) with a higher score indicating greater severity.

Time frame:
12 weeks
Reported as:
Mean · score on a scale
Change in HECSI Score From Baseline to Week 12
score on a scaleDelgocitinib Cream 20 mg/gAlitretinoin Capsules 30 mg Per Capsule
Change in HECSI Score From Baseline to Week 12-67.6 ± 3.37-51.5 ± 3.36
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Alitretinoin Capsules 30 mg Per Capsule · ANCOVA · p = <0.001 · Mean difference (net): -16.1 · 95% CI -23.28 to -8.86
SecondaryHECSI-90 at Week 12

The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score), with a higher score indicating greater severity. HECSI-90 is defined as at least 90% improvement in HECSI score from baseline.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
HECSI-90 at Week 12
ParticipantsDelgocitinib Cream 20 mg/gAlitretinoin Capsules 30 mg Per Capsule
HECSI-90 at Week 129665
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Alitretinoin Capsules 30 mg Per Capsule · Cochran-Mantel-Haenszel · p = =0.003 · Risk difference (rd): 12.6 · 95% CI 4.34 to 20.78
SecondaryIGA-CHE TS at Week 12.

The Investigator's Global Assessment for chronic hand eczema (IGA-CHE) is an instrument used in clinical trials to rate the severity of the participant's global chronic hand eczema (CHE) and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). IGA-CHE treatment success (IGA-CHE TS) is defined as an IGA-CHE score of 0 (clear) or 1 (almost clear) with a ≥2-step improvement from baseline.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
IGA-CHE TS at Week 12.
ParticipantsDelgocitinib Cream 20 mg/gAlitretinoin Capsules 30 mg Per Capsule
IGA-CHE TS at Week 12.6842
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Alitretinoin Capsules 30 mg Per Capsule · Cochran-Mantel-Haenszel · p = =0.004 · Risk difference (rd): 10.6 · 95% CI 3.31 to 17.87
SecondaryChange in HESD Itch Score (Weekly Average) From Baseline to Week 12

The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'itch' component.

Time frame:
12 weeks
Reported as:
Mean · score on a scale
Change in HESD Itch Score (Weekly Average) From Baseline to Week 12
score on a scaleDelgocitinib Cream 20 mg/gAlitretinoin Capsules 30 mg Per Capsule
Change in HESD Itch Score (Weekly Average) From Baseline to Week 12-3.0 ± 0.22-2.4 ± 0.21
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Alitretinoin Capsules 30 mg Per Capsule · ANCOVA · p = =0.005 · Mean difference (net): -0.7 · 95% CI -1.12 to -0.20
SecondaryChange in HESD Pain Score (Weekly Average) From Baseline to Week 12.

The Hand Eczema Symptom Diary (HESD) is an eDiary in which participants will assess the worst severity of 6 individual signs and symptoms of CHE over the past 24 hours using an 11-point numeric rating scale with anchors of 0 ='no (symptom)' and 10 ='severe (symptom)' throughout the trial on a daily basis. This endpoint will only assess the 'pain' component.

Time frame:
12 weeks
Reported as:
Mean · score on a scale
Change in HESD Pain Score (Weekly Average) From Baseline to Week 12.
score on a scaleDelgocitinib Cream 20 mg/gAlitretinoin Capsules 30 mg Per Capsule
Change in HESD Pain Score (Weekly Average) From Baseline to Week 12.-2.9 ± 0.23-2.3 ± 0.23
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Alitretinoin Capsules 30 mg Per Capsule · ANCOVA · p = =0.018 · Mean difference (net): -0.6 · 95% CI -1.08 to -0.10
SecondaryAUC of HECSI-90 From Baseline up to Week 24

The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score) with a higher score indicating greater severity. HECSI-90 is defined as at least 90% improvement in HECSI score from baseline. The area under the curve (AUC) at participant level will be determined as follows: 1 will be assigned when response is observed and 0 otherwise. The AUC is interpreted as number of days with 90% reduction in HECSI score until Week 24.

Time frame:
24 weeks
Reported as:
Mean · days with 90% reduction in HECSI score
AUC of HECSI-90 From Baseline up to Week 24
days with 90% reduction in HECSI scoreDelgocitinib Cream 20 mg/gAlitretinoin Capsules 30 mg Per Capsule
AUC of HECSI-90 From Baseline up to Week 2451.1 ± 4.1143.5 ± 4.22
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Alitretinoin Capsules 30 mg Per Capsule · ANCOVA · p = <0.001 · Mean difference (net): 14.3 · 95% CI 5.81 to 22.86
SecondaryAUC of Change From Baseline in DLQI Score up to Week 24

The Dermatology Life Quality Index (DLQI) is a validated questionnaire consisting of 10 items addressing the participant's perception of the impact of their skin disease on different aspects of their quality of life over the last week. The DLQI score is the sum of the 10 items (score ranging from 0 to 30); a high score is indicative of a poor quality of life. The area under the curve (AUC) at patient level will be determined from the change from baseline in DLQI score estimated as a piecewise linear function from Week 0 to Week 24. Differences will be analyzed with opposite sign to interpret positive area as improvement in scores and negative area as worsening.

Time frame:
24 weeks
Reported as:
Mean · days * DLQI score reduction
AUC of Change From Baseline in DLQI Score up to Week 24
days * DLQI score reductionDelgocitinib Cream 20 mg/gAlitretinoin Capsules 30 mg Per Capsule
AUC of Change From Baseline in DLQI Score up to Week 241124.7 ± 61.37790.7 ± 62.67
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Alitretinoin Capsules 30 mg Per Capsule · ANCOVA · p = <0.001 · Mean difference (net): 334.0 · 95% CI 195.69 to 472.26
SecondaryChange in HECSI Score From Baseline to Week 24

The Hand Eczema Severity Index (HECSI) is an instrument used in clinical trials to rate the severity of 6 clinical signs (erythema, infiltration/papulation, vesicles, fissures, scaling, and oedema) and the extent of the lesions in each of the 5 hand regions (fingertips, fingers \[except fingertips\], palm of hands, back of hands, and wrists) by use of standard scales. The HECSI score will range from 0 (lowest possible score) to 360 (highest possible score) with a higher score indicating greater severity.

Time frame:
24 weeks
Reported as:
Mean · score on a scale
Change in HECSI Score From Baseline to Week 24
score on a scaleDelgocitinib Cream 20 mg/gAlitretinoin Capsules 30 mg Per Capsule
Change in HECSI Score From Baseline to Week 24-69.6 ± 3.78-45.1 ± 3.77
Statistical analysis
  • Delgocitinib Cream 20 mg/g vs Alitretinoin Capsules 30 mg Per Capsule · ANCOVA · p = <0.001 · Mean difference (net): -24.5 · 95% CI -32.55 to -16.36
SecondaryNumber of Treatment-emergent AEs From Baseline up to Week 26

An adverse event (AE) will be considered treatment emergent if started after the first application of investigational medicinal product (IMP), or if started before the first application of IMP and worsened in severity after first dose of IMP.

Time frame:
26 weeks
Reported as:
Number · events
Number of Treatment-emergent AEs From Baseline up to Week 26
eventsDelgocitinib Cream 20 mg/gAlitretinoin Capsules 30 mg Per Capsule
Number of Treatment-emergent AEs From Baseline up to Week 26280620
SecondaryNumber of Treatment-emergent SAEs From Baseline up to Week 26

A serious adverse event (SAE) will be considered treatment emergent if started after the first application of investigational medicinal product (IMP), or if started before the first application of IMP and worsened in severity after first dose of IMP.

Time frame:
26 weeks
Reported as:
Number · events
Number of Treatment-emergent SAEs From Baseline up to Week 26
eventsDelgocitinib Cream 20 mg/gAlitretinoin Capsules 30 mg Per Capsule
Number of Treatment-emergent SAEs From Baseline up to Week 26512
SecondaryNumber of AEs Leading to IMP Discontinuation up to Week 24

The investigational medicinal product (IMP) will be discontinued permanently in case of an AE that, in the opinion of the investigator or sponsor's medical expert, contraindicates further dosing. The investigator will assess the relationship between investigational medicinal product (IMP) and the adverse event (AE).

Time frame:
24 weeks
Reported as:
Number · events
Number of AEs Leading to IMP Discontinuation up to Week 24
eventsDelgocitinib Cream 20 mg/gAlitretinoin Capsules 30 mg Per Capsule
Number of AEs Leading to IMP Discontinuation up to Week 24444

Adverse events

Collected over From baseline to Week 26. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Delgocitinib Cream 20 mg/g0/253 (0%)5/253 (2%)58/253 (22.9%)
Alitretinoin Capsules 30 mg Per Capsule0/247 (0%)12/247 (4.9%)143/247 (57.9%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventDelgocitinib Cream 20 mg/gAlitretinoin Capsules 30 mg Per Capsule
Gastrointestinal inflammationGastrointestinal disorders0/2531/247
Deep vein thrombosis postoperativeInjury, poisoning and procedural complications0/2531/247
Road traffic accidentInjury, poisoning and procedural complications0/2531/247
International normalised ratio increasedInvestigations0/2531/247
HyperkalaemiaMetabolism and nutrition disorders0/2531/247
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2531/247
Benign salivary gland neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2531/247
HeadacheNervous system disorders0/2531/247
ProstatitisReproductive system and breast disorders0/2531/247
Mediastinal cystRespiratory, thoracic and mediastinal disorders0/2531/247
Most frequent other events
Showing 10 of 21
Most frequent other events
EventDelgocitinib Cream 20 mg/gAlitretinoin Capsules 30 mg Per Capsule
HeadacheNervous system disorders10/25379/247
NasopharyngitisInfections and infestations30/25334/247
NauseaGastrointestinal disorders1/25314/247
Urinary tract infectionInfections and infestations1/25310/247
COVID-19Infections and infestations5/2539/247
HypercholesterolaemiaMetabolism and nutrition disorders0/2539/247
Dry skinSkin and subcutaneous tissue disorders3/2539/247
ErythemaSkin and subcutaneous tissue disorders1/2539/247
Lip dryGastrointestinal disorders0/2538/247
Upper respiratory tract infectionInfections and infestations6/2538/247

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Delgocitinib Cream 20 mg/gAlitretinoin Capsules 30 mg Per CapsuleTotal
<=18 years000
Between 18 and 65 years238233471
>=65 years162642
Age, Continuous
Age, Continuous(years)Delgocitinib Cream 20 mg/gAlitretinoin Capsules 30 mg Per CapsuleTotal
Mean45.4 ± 13.7844.0 ± 14.5644.7 ± 14.18
Sex: Female, Male
Sex: Female, Male(Participants)Delgocitinib Cream 20 mg/gAlitretinoin Capsules 30 mg Per CapsuleTotal
Female167167334
Male8792179
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Delgocitinib Cream 20 mg/gAlitretinoin Capsules 30 mg Per CapsuleTotal
Hispanic or Latino221436
Not Hispanic or Latino226241467
Unknown or Not Reported6410
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Delgocitinib Cream 20 mg/gAlitretinoin Capsules 30 mg Per CapsuleTotal
American Indian or Alaska Native224
Asian9514
Native Hawaiian or Other Pacific Islander011
Black or African American235
White237240477
More than one race167
Unknown or Not Reported325
Region of Enrollment
Region of Enrollment(participants)Delgocitinib Cream 20 mg/gAlitretinoin Capsules 30 mg Per CapsuleTotal
Canada252954
Austria235
Norway112
Poland8991180
Italy13922
United Kingdom246
Slovakia9514
France141630
Germany6373136
Spain362864
08

Study locations

102 sites
  • LEO Pharma Investigational Site
    Graz, 8036, Austria
  • LEO Pharma Investigational Site
    Linz, 4010, Austria
  • LEO Pharma Investigational Site
    Linz, 4021, Austria
  • LEO Pharma Investigational Site
    Calgary, T2J 7E1, Canada
  • LEO Pharma Investigational Site
    Calgary, T2W 4X9, Canada
  • LEO Pharma Investigational Site
    Edmonton, T6G 1C3, Canada
  • LEO Pharma Investigational Site
    Edmonton, T6W0J5, Canada
  • LEO Pharma Investigational Site
    Guelph, N1L 0B7, Canada
  • LEO Pharma Investigational Site
    London, N6A 2C2, Canada
  • LEO Pharma investigational site
    London, N6A 5R9, Canada
  • LEO Pharma investigational site
    Markham, L3P 1X3, Canada
  • LEO Pharma investigational site
    Niagara Falls, L2H 1H5, Canada
  • LEO Pharma Investigational Site
    North York, M2N 3A6, Canada
  • LEO Pharma investigational site
    Québec, G1W 4R4, Canada
  • LEO Pharma Investigational Site
    Red Deer, T4P 1K4, Canada
  • LEO Pharma investigational site
    Sherbrooke, J1G 1X9, Canada
  • LEO Pharma Investigational Site
    Antony, 92160, France
  • LEO Pharma Investigational Site
    Martigues, 13500, France
  • LEO Pharma Investigational Site
    Montpellier, 34295, France
  • LEO Pharma Investigational Site
    Nice, 06000, France
  • LEO Pharma investigational site
    Nice, 6202, France
  • LEO Pharma Investigational Site
    Reims, 51100, France
  • LEO Pharma Investigational Site
    Toulon, 83000, France
  • LEO Pharma Investigational Site
    Augsburg, 86163, Germany
  • LEO Pharma Investigational Site
    Berlin, 10789, Germany
  • LEO Pharma Investigational Site
    Berlin, 13055, Germany
  • LEO Pharma Investigational Site
    Bochum, 44791, Germany
  • LEO Pharma Investigational Site
    Bochum, 44793, Germany
  • LEO Pharma Investigational Site
    Bonn, 53111, Germany
  • LEO Pharma Investigational Site
    Darmstadt, 64283, Germany
  • LEO Pharma Investigational Site
    Dresden, 01307, Germany
  • LEO Pharma Investigational Site
    Erlangen, 91054, Germany
  • LEO Pharma Investigational Site
    Essen, 45147, Germany
  • LEO Pharma Investigational Site
    Frankfurt, 60590, Germany
  • LEO Pharma Investigational Site
    Friedrichshafen, 88045, Germany
  • LEO Pharma Investigational Site
    Gera, 07548, Germany
  • LEO Pharma Investigational Site
    Göttingen, 37075, Germany
  • LEO Pharma Investigational Site
    Halle, 06110, Germany
  • LEO Pharma Investigational Site
    Hamburg, 22391, Germany
  • LEO Pharma Investigational Site
    Heidelberg, 69120, Germany
  • LEO Pharma Investigational Site
    Langenau, 89129, Germany
  • LEO Pharma Investigational Site
    Lohne, 49393, Germany
  • LEO Pharma Investigational Site
    Mainz, 55131, Germany
  • LEO Pharma Investigational Site
    Marburg, 35043, Germany
  • LEO Pharma Investigational Site
    Memmingen, 87700, Germany
  • LEO Pharma Investigational Site
    München, 80337, Germany
  • LEO Pharma Investigational Site
    München, 80802, Germany
  • LEO Pharma Investigational Site
    Oldenburg, 26133, Germany
  • LEO Pharma Investigational Site
    Osnabrück, 49074, Germany
  • LEO Pharma Investigational Site
    Wuppertal, 42287, Germany
  • LEO Pharma Investigational Site
    Bologna, 40138, Italy
  • LEO Pharma Investigational Site
    Brescia, 25123, Italy
  • LEO Pharma Investigational Site
    Catania, 95123, Italy
  • LEO Pharma Investigational Site
    Catanzaro, 88100, Italy
  • LEO Pharma Investigational Site
    Genova, 16132, Italy
  • LEO Pharma Investigational Site
    Lucca, 55100, Italy
  • LEO Pharma Investigational Site
    Milano, 20089, Italy
  • LEO Pharma Investigational Site
    Pavia, 27100, Italy
  • LEO Pharma Investigational Site
    Pisa, 56126, Italy
  • LEO Pharma Investigational Site
    Terracina, 4019, Italy
  • LEO Pharma Investigational Site
    Stavanger, 4011, Norway
  • LEO Pharma Investigational Site
    Tromsø, 9038, Norway
  • LEO Pharma Investigational Site
    Białystok, 15-794, Poland
  • LEO Pharma investigational site
    Bydgoszcz, 85-796, Poland
  • LEO Pharma Investigational Site
    Chorzów, 41-500, Poland
  • LEO Pharma Investigational Site
    Gdańsk, 80-546, Poland
  • LEO Pharma Investigational Site
    Gdynia, 81-338, Poland
  • LEO Pharma Investigational Site
    Katowice, 40-081, Poland
  • LEO Pharma investigational site
    Katowice, 40-611, Poland
  • LEO Pharma investigational site
    Katowice, 40-851, Poland
  • LEO Pharma Investigational Site
    Kraków, 30-033, Poland
  • LEO Pharma Investigational Site
    Kraków, 30-727, Poland
  • LEO Pharma Investigational Site
    Kraków, 31-501, Poland
  • LEO Pharma Investigational Site
    Lublin, 20-080, Poland
  • LEO Pharma Investigational Site
    Poznań, 61-731, Poland
  • LEO Pharma Investigational Site
    Strzelce Opolskie, 47-100, Poland
  • LEO Pharma Investigational Site
    Szczecin, 71-434, Poland
  • LEO Pharma Investigational Site
    Warszawa, 02-677, Poland
  • LEO Pharma Investigational Site
    Wrocław, 51-685, Poland
  • LEO Pharma Investigational Site
    Łódź, 90-436, Poland
  • LEO Pharma Investigational Site
    Bratislava, 851 01, Slovakia
  • LEO Pharma Investigational Site
    Svidník, 089 01, Slovakia
  • LEO Pharma Investigational Site
    Trnava, 917 75, Slovakia
  • LEO Pharma Investigational Site
    Alcalá de Henares, 28805, Spain
  • LEO Pharma Investigational Site
    Alicante, 03010, Spain
  • LEO Pharma Investigational Site
    Badalona, 08916, Spain
  • LEO Pharma Investigational Site
    Barcelona, 08003, Spain
  • LEO Pharma Investigational Site
    Barcelona, 08025, Spain
  • LEO Pharma Investigational Site
    Córdoba, 14004, Spain
  • LEO Pharma Investigational Site
    Hospitalet de Llobregat, 08907, Spain
  • LEO Pharma Investigational Site
    Madrid, 28006, Spain
  • LEO Pharma Investigational Site
    Madrid, 28034, Spain
  • LEO Pharma Investigational Site
    Madrid, 28040, Spain
  • LEO Pharma Investigational Site
    Madrid, 28041, Spain
  • LEO Pharma investigational site
    Málaga, 29009, Spain
  • LEO Pharma investigational site
    Pontevedra, 36071, Spain
  • LEO Pharma Investigational Site
    Sevilla, 41009, Spain
  • LEO Pharma Investigational Site
    Valencia, 46014, Spain
  • LEO Pharma Investigational Site
    Valencia, 46026, Spain
  • LEO Pharma Investigational Site
    Zaragoza, 50009, Spain

Showing the first 100 of 102 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Gimenez-Arnau AM, Pinter A, Sondermann W, Reguiai Z, Woolf R, Lynde C, Legat FJ, Costanzo A, Silvestre JF, Mellerup N, Osterdal ML, Plohberger U, Ryttig L, Bauer A; trial investigators. Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial. Lancet. 2025 Apr 16:S0140-6736(25)00001-7. doi: 10.1016/S0140-6736(25)00001-7. Online ahead of print. PubMed 40252681 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Nov 2023, 16 months.

Results were first posted in Mar 2025, 1 year 4 months after primary completion.

Of 66 industry-sponsored phase 3 interventional studies under Eczema, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 26. This study's 16 months is below that.

Counting every sponsor, half of 71 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2022
First posted
Feb 28, 2022
StartActual
Jun 15, 2022
Primary completionActual
Nov 8, 2023
CompletionActual
Dec 5, 2023
Results first posted
Mar 14, 2025
Last update
May 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05259722
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Feb 28, 2022
Start date
Jun 15, 2022
Primary completion
Nov 8, 2023
Completion
Dec 5, 2023
Results posted
Mar 14, 2025
Last update
May 9, 2025

Study contacts

Medical Expert
study director · LEO Pharma

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Delgocitinib

Start the discussion